Patents by Inventor Mark Stuart

Mark Stuart has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6143773
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof: ##STR1## wherein A is C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-6 cycloalkyl, arylC.sub.1-6 alkyl, aryl, S(O).sub.p R.sup.1, OR.sup.1 or NR.sup.1 R.sup.12 ;B is optionally substituted 5- or 6-membered heteroaromatic ring or C(O)NR.sup.10 R.sup.11 ;R.sup.1 is hydrogen, optionally substituted C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-6 cycloalkyl or C.sub.3-6 cycloalkenyl, optionally substituted aryl, arylC.sub.1-6 alkyl, arylC.sub.2-6 alkenyl or arylC.sub.2-6 alkynyl or an optionally substituted 5- or 6-membered heteroaromatic ring;R.sup.2 and R.sup.3 are hydrogen or C.sub.1-6 alkyl;R.sup.4 is hydrogen, C.sub.1-8 alkyl, C.sub.2-8 alkenyl, C.sub.2-8 alkynyl, aryl or CH.sub.2 (CO).sub.m NR.sup.8 R.sup.9 ;R.sup.5 is NR.sup.6 R.sup.7, C.sub.1-6 alkyl or C.sub.1-6 alkoxy;R.sup.6 is independently as defined for R.sup.4 ;R.sup.
    Type: Grant
    Filed: April 22, 1999
    Date of Patent: November 7, 2000
    Assignee: Merck Sharp & Dohme Limited
    Inventors: Howard Barff Broughton, Mark Stuart Chambers
  • Patent number: 6048859
    Abstract: Substituted heterocycles of the general structural formula: ##STR1## are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, asthma and emesis, and calcium channel blockers useful in the treatment of cardiovascular conditions such as angina, hypertension or ischemia.
    Type: Grant
    Filed: February 16, 1999
    Date of Patent: April 11, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Conrad P. Dorn, Paul E. Finke, Jeffrey J. Hale, Malcolm Maccoss, Sander G. Mills, Shrenik K. Shah, Mark Stuart Chambers, Timothy Harrison, Tamara Ladduwahetty, Brian John Williams
  • Patent number: 5998415
    Abstract: A class of piperazinones, homopiperazinones and thione analogues thereof, substituted at the 1-position by an optionally substituted alkenyl, alkynyl, aryl-alkyl or heteroaryl-alkyl moiety, and linked at the 4-position via an alkylene spacer to a fused bicyclic heteroaromatic moiety, typically indolyl, are selective agonists of 5-HT.sub.1 -like receptors, being potent agonists of the human 5-HT.sub.1D.alpha. receptor subtype while possessing at least a 10-fold selective affinity for the 5-HT.sub.1D.alpha. receptor subtype relative to the 5-HT.sub.1D.beta. subtype; they are therefore useful in the treatment and/or prevention of clinical conditions, in particular migraine and associated disorders, for which a subtype-selective agonist of 5-HT.sub.1D receptors is indicated, while eliciting fewer side-effects, notably adverse cardiovascular events, than those associated with non-subtype-selective 5-HT.sub.1D receptor agonists.
    Type: Grant
    Filed: April 17, 1998
    Date of Patent: December 7, 1999
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Mark Stuart Chambers, Sarah Christine Hobbs, Leslie Joseph Street
  • Patent number: 5989315
    Abstract: Air is supplied along a pipeline to an apparatus for separating an oxygen-enriched gas stream from the air by vacuum swing adsorption. The oxygen-enriched gas stream is supplied to a burner which fires into a furnace. A hot gas stream leaves the furnace through an outlet. Steam is raised from the hot gas in a waste heat boiler. Steam so raised flows through one or more of the eductors to draw through a pipeline the vacuum necessary for the operation of the vacuum swing adsorption apparatus.
    Type: Grant
    Filed: February 5, 1998
    Date of Patent: November 23, 1999
    Assignee: The BOC Group plc
    Inventors: David Mark Stuart, John Robert Coates
  • Patent number: 5985006
    Abstract: A vacuum swing adsorption apparatus for separating a gas mixture includes a pipeline along which the vacuum is able to be drawn. The apparatus is provided with a plurality of eductors each connected to the pipeline 6 and in parallel with the other eductor respective stop valves. The stop valves are arranged and operable so as to select the number of eductors in communication with the pipeline. Thus the degree of vacuum to which the apparatus is subjected may be varied.
    Type: Grant
    Filed: February 5, 1998
    Date of Patent: November 16, 1999
    Assignee: The BOC Group plc
    Inventors: David Mark Stuart, John Robert Coates
  • Patent number: 5981529
    Abstract: A class of 1-[3-(1H-indol-3-yl)propyl]-4-(2-phenylethyl)piperazine derivatives, substituted at the 5-position of the indole nucleus by a five-membered heteroaromatic moiety, on one or other of the ethylene carbon atoms of the phenethyl moiety by halogen, trifluoromethyl, alkyl, hydroxyalkyl or alkoxyalkyl, and optionally on the phenyl ring of the phenethyl moiety by halogen, trifluoromethyl, alkoxy or an oxazolidinone group and optionally by one or two further substituents, are selective agonists of 5-HT.sub.1 -like receptors, being potent agonists of the human 5-HT.sub.1D .alpha. receptor subtype whilst possessing at least a 10-fold selective affinity for the 5-HT.sub.1D .alpha. receptor subtype relative to the 5-HT.sub.1D .beta. subtype; they are therefore useful in the treatment and/or prevention of clinical conditions, in particular migraine and associated disorders, for which a subtype-selective agonist of 5-HT.sub.
    Type: Grant
    Filed: March 18, 1998
    Date of Patent: November 9, 1999
    Assignee: Merck Sharp & Dohme Limited
    Inventors: Raymond Baker, Mark Stuart Chambers, Sarah Christine Hobbs, Angus Murray MacLeod, Austin John Reeve, Francine Sternfeld, Leslie Joseph Street
  • Patent number: 5973156
    Abstract: A class of substituted piperidine and tetrahydropyridine derivatives, linked through the 4-position thereof via an alkylene chain to a fused bicyclic heteroaromatic moiety such as indolyl, and further substituted at the 1-position by an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl-alkyl, aryl-alkyl or heteroaryl-alkyl moiety, are selective agonists of 5-HT.sub.1 -like receptors, being potent agonists of the human 5-HT.sub.1D.spsb..alpha. receptor subtype whilst processing at least a 10-fold selective affinity for the 5-HT.sub.1D.spsb..alpha. receptor subtype relative to the 5-HT.sub.1D.spsb..beta. subtype; they are therefore useful in the treatment and/or prevention of clinical conditions, in particular migraine and associated disorders, for which a subtype-selective agonist of 5-HT.sub.1D receptors is indicated, whilst eliciting fewer side-effects, notably adverse cardiovascular events, than those associated with non-subtype-selective 5-HT.sub.1D receptor agonists.
    Type: Grant
    Filed: May 13, 1998
    Date of Patent: October 26, 1999
    Assignee: Merck Sharp & Dome Ltd.
    Inventors: Mark Stuart Chambers, Sarah Christine Hobbs, Tamara Ladduwahetty, Angus Murray MacLeod, Kevin John Merchant
  • Patent number: 5949424
    Abstract: A method, system, and computer program product for accelerated shading of an object surface by bump mapping in tangent space. A tangent space transform module builds a tangent space transform matrix M(p) having elements comprised of normal, tangent, and binormal vector components determined at a surface point on the object surface. The tangent space transform module further transforms shading vectors, such as, lighting and viewing vectors, into a tangent space defined by the tangent space transform matrix and outputs corresponding tangent space shading vectors. A bump mapping module performs vector operations between one or more tangent space shading vectors and a perturbed normal N' in tangent space. A texture memory stores a surface dependent or a surface independent tangent space perturbed normal texture map. The lighting module computes a shading value for the surface point based on the vector operations.
    Type: Grant
    Filed: February 28, 1997
    Date of Patent: September 7, 1999
    Assignee: Silicon Graphics, Inc.
    Inventors: Brian Keith Cabral, Mark Stuart Peercy, John Milligan Airey
  • Patent number: 5925638
    Abstract: A class of 1-?3-(1H-indol-3-yl)propyl!-4-benzylpiperazine derivatives of formula I, substituted at the 5-position of the indole nucleus by a 1,2,4-triazol-4-yl moiety, and on the methylene linkage of the benzyl moiety by a range of substituted alkyl groups, are selective agonists of 5-HT.sub.1 -like receptors, being potent agonists of the human 5-HT.sub.1D.alpha. receptor subtype whilst possessing at least a 10-fold selective affinity for the 5-HT.sub.1D.alpha. receptor subtype relative to the 5-HT.sub.1D.beta. subtype; they are therefore useful in the treatment and/or prevention of clinical conditions, in particular migraine and associated disorders, for which a subtype-selective agonist of 5-HT.sub.1D receptors is indicated, whilst eliciting fewer side-effects, notably adverse cardiovascular events, than those associated with non-subtype-selective 5-HT.sub.1D receptor agonists.
    Type: Grant
    Filed: April 28, 1998
    Date of Patent: July 20, 1999
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Mark Stuart Chambers, Sarah Christine Hobbs, Leslie Joseph Street
  • Patent number: 5919783
    Abstract: Compounds of formula (I), or a salt or prodrug thereof, wherein Z represents an optionally substituted five-membered heteroaromatic ring selected from furan, thiophene, pyrrole, oxazole, thiazole, isoxazole, isothiazole, imidazole, pyrazole, oxadiazole, thiadiazole, triazole, and tetrazole; E represents a chemical bond or a straight or branched alkylene chain containing from 1-4 carbon atoms; Q represents a straight or branched alkylene chain containing from 1-6 carbon atoms; T represents nitrogen or CH; R.sup.1 represents aryl(C.sub.1-6)alkyl or heteroaryl(C.sub.1-6)alkyl, either of which groups may be optionally substituted; and R.sup.2 represents hydrogen or C.sub.1-6 alkyl are selective agonists of 5-HT.sub.1 -like receptors, being potent agonists of the human 5-HT.sub.1D.alpha. receptor subtype whilst possessing at least a 10-fold selective affinity for the 5-HT.sub.1D.alpha. receptor subtype relative to the 5-HT.sub.1D.beta.
    Type: Grant
    Filed: January 21, 1997
    Date of Patent: July 6, 1999
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Mark Stuart Chambers, Victor Giulio Matassa, Leslie Joseph Street
  • Patent number: 5880736
    Abstract: A method, system, and computer program product are provided for accelerated shading of an object surface by bump mapping in tangent space or object space. A tangent space transform module builds a tangent space transform matrix M(p) having elements comprised of normal, tangent, and binormal vector components determined at a surface point on the object surface. The tangent space transform module further transforms shading vectors, such as, lighting and viewing vectors, into a tangent space defined by the tangent space transform matrix and outputs corresponding tangent space shading vectors. A bump mapping module performs vector operations between one or more tangent space shading vectors and a perturbed normal N' in tangent space. A texture memory stores a surface dependent or a surface independent tangent space perturbed normal texture map. The lighting module computes a shading value for the surface point based on the vector operations.
    Type: Grant
    Filed: June 20, 1997
    Date of Patent: March 9, 1999
    Assignee: Silicon Graphics, Inc.
    Inventors: Mark Stuart Peercy, John Milligan Airey, Brian Keith Cabral
  • Patent number: 5873912
    Abstract: Improved processes for the exhaust dyeing of cellulosic fibers with sulphur dyes in the presence of non-sulphide reducing agents wherein the dyeing of the textile substrate is performed in a closed vessel in an atmosphere of reduced oxygen level and then oxidizing.
    Type: Grant
    Filed: January 28, 1997
    Date of Patent: February 23, 1999
    Assignee: Clariant Finance (BVI) Limited
    Inventor: Mark Stuart Carlough
  • Patent number: 5872116
    Abstract: Substituted heterocycles of the general structural formula: ##STR1## are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, asthma and emesis, and calcium channel blockers useful in the treatment of cardiovascular conditions such as angina, hypertension or ischemia.
    Type: Grant
    Filed: October 28, 1997
    Date of Patent: February 16, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Conrad P. Dorn, Paul E. Finke, Jeffrey J. Hale, Malcolm Maccoss, Sander G. Mills, Shrenik K. Shah, Mark Stuart Chambers, Timothy Harrison, Tamara Ladduwahetty, Brian John Williams
  • Patent number: 5854268
    Abstract: A class of substituted azetidine, pyrrolidine and piperidine derivatives are selective agonists of 5-HT.sub.1 -like receptors, being potent agonists of the human 5-HT.sub.1D.alpha. receptor subtype whilst possessing at least a 10-fold selective affinity for the 5-HT.sub.1D.alpha. receptor subtype relative to the 5-HT.sub.1D.beta. subtype; they are therefore useful in the treatment and/or prevention of clinical conditions, in particular migraine and associated disorders, for which a subtype-selective agonist of 5-HT.sub.1D receptors is indicated, whilst eliciting fewer side-effects, notably adverse cardiovascular events, than those associated with non-subtype-selective 5-HT.sub.1D receptor agonists.
    Type: Grant
    Filed: January 22, 1997
    Date of Patent: December 29, 1998
    Assignee: Merck Sharp & Dohme, Ltd.
    Inventors: Raymond Baker, Sylvie Bourrain, Jose Luis Castro Pineiro, Mark Stuart Chambers, Alexander Richard Guiblin, Sarah Christine Hobbs, Richard Alexander Jelley, Andrew Madin, Victor Giulio Matassa, Austin John Reeve, Michael Geoffrey Russell, Graham Andrew Showell, Francine Sternfeld, Leslie Joseph Street, Monique Bodil Van Niel
  • Patent number: 5849746
    Abstract: A class of 1,4-disubstituted piperazine derivatives, further substituted on one of the carbon atoms of the piperazine ring, are selective agonists of 5-HT.sub.1 -like receptors, being potent agonists of the human 5-HT.sub.1D.alpha. receptor subtype whilst possessing at least a 10-fold selective affinity for the 5-HT.sub.1D.alpha. receptor subtype relative to the 5-HT.sub.1D.beta. subtype; they are therefore useful in the treatment and/or prevention of clinical conditions, in particular migraine and associated disorders, for which a subtype-selective agonist of 5-HT.sub.1D receptors is indicated, while eliciting fewer side-effects, notably adverse cardiovascular events, than those associated with non-subtype-selective 5-HT.sub.1D receptor agonists.
    Type: Grant
    Filed: July 22, 1997
    Date of Patent: December 15, 1998
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Mark Stuart Chambers, Angus Murray MacLeod, Victor Giulio Matassa
  • Patent number: 5826986
    Abstract: An improved grease-expelling wheel bearing assembly (1) comprises a grease expelling seal (3), and a grease distributor (5). The grease distributor (5) comprises a collar (7) for mounting about the shaft (9) of a rotor nut (11) and, projecting from the collar (7), at least one grease spreading blade (13) extending radially outwards from the collar towards the assembly housing (15), part (17) of the area between the collar (7) and the housing (15) not being covered by a blade (13), the arrangement being such that rotation of the blade (13) causes grease expelled from the bearing seal (3) to be spread evenly around the circumference of the seal, without preventing its contact with the rotor nut (11).
    Type: Grant
    Filed: July 30, 1997
    Date of Patent: October 27, 1998
    Assignee: Jaguar Cars, Ltd.
    Inventors: David Paul Adkins, Mark Stuart Ford
  • Patent number: 5807857
    Abstract: Compounds of formula (I), or a salt or prodrug thereof, wherein Z represents an optionally substituted five-membered heteroaromatic ring selected from furan, thiophene, pyrrole, oxazole, thiazole, isoxazole, isothiazole, imidazole, pyrazole, oxadiazole, thiadiazole, triazole and tetrazole; E represents a chemical bond or a straight or branched alkylene chain containing from 1 to 4 carbon atoms; Q represents a straight or branched alkylene chain containing from 1 to 6 carbon atoms, optionally substituted in any position by a hydroxy group; T represents nitrogen or CH; U represents nitrogen or C--R.sup.2 ; V represents oxygen, sulphur or N--R.sup.3 ; --F--G-- represents --CH2--N--, --CH2--CH-- or --CH.dbd.C--; R.sup.1 represents C.sub.3-6 alkenyl, C.sub.3-6 alkynyl, aryl(C.sub.1-6)alkyl or heteroaryl(C.sub.1-6)alkyl, any of which groups may be optionally substituted; and R.sup.2 and R.sup.3 independently represent hydrogen or C.sub.
    Type: Grant
    Filed: November 15, 1996
    Date of Patent: September 15, 1998
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Jose Luis Castro Pineiro, Mark Stuart Chambers, Sarah Christine Hobbs, Austin John Reeve, Graham Andrew Showell, Leslie Joseph Street, Victor Giulio Matassa
  • Patent number: 5719147
    Abstract: Substituted heterocycles of the general structural formula: ##STR1## are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, asthma and emesis, and calcium channel blockers useful in the treatment of cardiovascular conditions such as angina, hypertension or ischemia.
    Type: Grant
    Filed: September 8, 1995
    Date of Patent: February 17, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Conrad P. Dorn, Paul E. Finke, Jeffrey J. Hale, Malcolm MacCoss, Sander G. Mills, Shrenik K. Shah, Mark Stuart Chambers, Timothy Harrison, Tamara Ladduwahetty, Brian John Williams
  • Patent number: 5681833
    Abstract: Compounds of Formula (I), and salts and prodrugs thereof, wherein said formula, R.sup.1 represents certain optionally substituted alkyl or C.sub.3-7 cycloalkyl; R.sup.2 represents (II) or (III), where m is 0, 1, 2 or 3; R.sup.9 is H or C.sub.1-6 alkyl; R.sup.10 is imidazolyl, triazolyl or tetrazolyl, and R.sup.11 is H, C.sub.1-6 alkyl or halo; R.sup.3 is C.sub.1-6 alkyl, halo or NR.sup.6 R.sup.7 ; R.sup.4 is C.sub.1-7 alkyl, C.sub.3-10 cycloalkyl, C.sub.3-10 cycloalkylC.sub.1-4 alkyl, C.sub.6-10 bicycloalkyl, optionally substituted aryl, or NR.sub.12 R.sub.13 ; R.sup.5 is H or C.sub.1-4 alkyl; n is 0, 1, 2 or 3; which are CCK and/or gastrin antagonists useful in therapy.
    Type: Grant
    Filed: September 20, 1994
    Date of Patent: October 28, 1997
    Assignee: Merck, Sharp & Dohme Ltd.
    Inventors: Jose Luis Castro Pineiro, Mark Stuart Chambers, Sarah Christine Hobbs, Victor Giulio Matassa
  • Patent number: 5681948
    Abstract: A two-stage method for the preparation of polyol fatty acid polyesters is provided. The resulting polyol fatty acid polyesters are very lightly colored (i.e., colorless to slightly yellow) and have a high degree of substitution with fatty acid groups. The first stage of this two-stage method is a solvent-based esterification reaction; the second stage is an essentially solvent-free esterification reaction. In the first stage, a polyol in a solvent (e.g., sucrose in dimethylsulfoxide)) is reacted with fatty acid lower alkyl esters at relatively low temperatures using an alkaline salt catalyst. After the desired degree of esterification is obtained, the resulting partially-esterified polyol fatty acid polyesters and the solvent-containing phase are separated.
    Type: Grant
    Filed: March 6, 1995
    Date of Patent: October 28, 1997
    Assignee: Kraft Foods, Inc.
    Inventors: Mark Stuart Miller, Leslie George West, Robert Charles Dinwoodie, Richard S. Silver